Abstracts tagged "interstitial lung disease"

Abstract Number: 0808 • ACR Convergence 2023
Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System
Bryant England¹, Tate Johnson¹, Yangyuna Yang¹, Punyasha Roul¹, Daniel Hershberger¹, Brian Sauer², Grant Cannon³, Joshua Baker⁴ and Ted R Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There are currently no clinical practice guidelines for monitoring RA-associated interstitial lung disease (RA-ILD). Pulmonary function tests (PFTs) and chest computed tomography (CT) imaging…
Abstract Number: 1240 • ACR Convergence 2023
Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash
Ilaria Maccora¹, Patricia Vega-Fernandez², Kimberly Risma³ and Grant Schulert⁴, ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Division of Rheumatology, Cincinnati Children's Hospital, Medical Centre, Cincinnati, OH, ³Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: STING-associated vasculopathy with onset in infancy (SAVI) is characterized by systemic inflammation, skin vasculopathy and interstitial lung disease. However, since the initial description knowledge…
Abstract Number: 1704 • ACR Convergence 2023
Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma
gerlando Natalello¹, enrico De Lorenzis¹, Ludovica Berardini², lucrezia verardi¹, pier giacomo Cerasuolo¹, Alfredo Papa³, Italo De Vitis³, Francesco Varone², Luca Richeldi², Maria Antonietta D'Agostino¹ and Silvia Bosello¹, ¹Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ²Division of Pulmonology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ³Division of Gastroenterology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and disease-related death in systemic sclerosis (SSc). Esophageal disease is common in SSc, and…
Abstract Number: 2140 • ACR Convergence 2023
Serum Alarmins and the Risk of Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Ted R Mikuls¹, Bryant England², Harlan Sayles², Tate Johnson², Michael Duryee², Carlos Hunter², Joshua Baker³, Gail Kerr⁴, Gary Kunkel⁵, Grant Cannon⁶, Brian Sauer⁷, K Wysham⁸, Amy Joseph⁹, Beth Wallace¹⁰, Geoffrey Thiele² and Jill Poole², ¹Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁸VA Puget Sound/University of Washington, Seattle, WA, ⁹Washington University / St. Louis VA, St. Louis, MO, ¹⁰Ann Arbor VA, Ann Arbor, MI
Background/Purpose: Alarmins are proteins found in the nuclei of epithelial, endothelial, and immune cells that are released following cell damage and act as stress signals.…
Abstract Number: 2594 • ACR Convergence 2023
Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Oliver Distler¹, Madelon Vonk², Arata Azuma³, Maureen Mayes⁴, Dinesh Khanna⁵, Kristin B Highland⁶, Gerrit Toenges⁷, Margarida Alves⁸ and Yannick Allanore⁹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pulmonary Medicine and Oncology, Nippon Medical School, Tokyo, Japan, and Meisei Hospital, Saitama, Japan, ⁴Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁵University of Michigan, Ann Arbor, MI, ⁶Cleveland Clinic, Cleveland, OH, ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France
Background/Purpose: The SENSCIS trial enrolled patients with SSc-ILD without a requirement for them to have evidence of recent progression. During the trial, nintedanib reduced the…
Abstract Number: 0293 • ACR Convergence 2023
Characteristics and Outcomes of Idiopathic Inflammatory Myositis Associated Interstitial Lung Disease in Rural Appalachia
FNU Rida Ul Jannat, Sayanika Kaur, Bathmapriya Balakrishnan, Vishal Deepak, Bhanusowmya Buragamadagu, Rachel Salyer and Ty Landis, West Virginia University Hospital, Morgantown, WV
Background/Purpose: Interstitial lung disease (ILD) can affect up to 30% of the patients with idiopathic inflammatory myositis (IIM) and contributes significantly towards morbidity and mortality…
Abstract Number: 0644 • ACR Convergence 2023
Prediction of Stable SSc-ILD Depends on Definition of ILD Progression
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Carina Mihai⁶, Oyvind Midtvedt¹, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: Progression of interstitial lung disease (ILD) reduces long-term survival in patients with systemic sclerosis (SSc), and aggressive treatment and tight monitoring should be considered.…
Abstract Number: 0939 • ACR Convergence 2023
HRCT-derived Delta Radiomic Features Classify Response to Anti-Fibrotic Treatment in Experimental and Human Fibrosing Interstitial Lung Disease
David Lauer¹, Luca Romano Kolly¹, Hubert Gabrys², Matthias Brunner¹, Malgorzata Anna Maciukiewicz¹, Thomas Frauenfelder³, Stephanie Tanadini-Lang², Anne-Christine Uldry⁴, Manfred Heller⁴, Kerstin Klein⁵, Oliver Distler⁶, Janine Gote-Schniering¹ and Britta Maurer⁷, ¹University Hospital Bern, Bern, Switzerland, ²University Hospital Zurich, Zurich, Switzerland, ³Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University of Bern, Bern, Switzerland, ⁵Department of Rheumatology and Immunology, University Hospital Bern, Bern, Switzerland, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷University Hospital Bern, University Bern, Bern, Switzerland
Background/Purpose: Quantification of response to anti-fibrotic drugs in patients with fibrosing interstitial lung disease (ILD) relies on repeated pulmonary function tests (PFT) and visual evaluation…
Abstract Number: 1269 • ACR Convergence 2023
The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes
Gregory McDermott¹, Keigo Hayashi¹, Pierre-Antoine Juge², Ritu Gill¹, Suzanne Byrne¹, Staci Gagne¹, Kathleen Vanni¹, Emily Kowalski¹, Grace Qian¹, Katarina Bade³, Alene Saavedra¹, Yumeko Kawano¹, Michael Diiorio³, Taylor Wolfgang¹, Edy Kim¹, Paul Dellaripa³, Michael Weinblatt⁴, Nancy Shadick³, Tracy J. Doyle¹ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Harvard Medical School, Waban, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is a heterogenous condition encompassing multiple subtypes with varying histopathology, prognosis, and potential treatment options. The most common RA-ILD…
Abstract Number: 1724 • ACR Convergence 2023
Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Attenuates Experimental Pulmonary Fibrosis Through Mitochondria Transfer Mediated Anti-apoptotic and Immunomodulatory Effects
Hanna Lee¹, Suhee Kim², Mingyo Kim², Ok-Yi Jeong³ and Sang-Il Lee², ¹Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, South Korea, ²Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Hospital, JinJu, South Korea, ³Division of Rheumatology, Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, South Korea
Background/Purpose: Interstitial lung disease (ILD) is a serious condition characterized by inflammation and fibrosis in the lung interstitium. The important subtypes of ILD include idiopathic…
Abstract Number: 2158 • ACR Convergence 2023
Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON
Eric Matteson¹, Danielle Antin-Ozerkis², Francesco Bonella³, Nazia Chaudhuri⁴, Vincent Cottin⁵, Heiko Mueller⁶, Steven Sambevski⁷ and Wim A Wuyts⁸, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ²Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT, ³Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ⁴North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom, ⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁸Unit for Interstitial Lung Diseases, Department of Pulmonary Medicine, University Hospitals Leuven, Leuven, Belgium
Background/Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis, nintedanib reduced the rate of decline in forced vital capacity (FVC) compared with placebo,…
Abstract Number: 2595 • ACR Convergence 2023
A Randomized Controlled Trial to Compare the Efficacy and Safety of Tacrolimus with Mycophenolate Mofetil in Patients with Systemic Sclerosis – Interstitial Lung Disease ( INSIST TRIAL)
Shefali Khanna Sharma¹, Jithin Mathew¹, Chirag Kopp¹, Varun Dhir², Sahajal Dhooria³, Anindita Sinha¹ and Sanjay Jain¹, ¹Post Graduate Institute of Medical Education and Research, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³PGI CHANDIGARH, Chandigarh, India
Background/Purpose: Interstitial lung disease in systemic sclerosis(SSc-ILD) is heterogeneous with limited therapeutic options. Mycophenolate mofetil (MMF) is the most commonly used first line agent for…
Abstract Number: 0296 • ACR Convergence 2023
Does Presence of Anti-SSa and Ro52 Influence the Progression of Interstitial Lung Disease (ILD) in Idiopathic Inflammatory Myopathies (IIM)
Sonali Narain¹, Can Hu², Michael Liu¹, Kourosh Shargani³ and Galina Marder¹, ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Fort Lee, NJ, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
Background/Purpose: Anti-SSa and Ro52 are commonly present in IIM. We previously reported an association of a more severe early course of IIM-ILD with positive Ro52.…
Abstract Number: 0645 • ACR Convergence 2023
Continuous Progressive ILD in Systemic Sclerosis Is Associated with Mortality
Anna-Maria Hoffmann-Vold¹, Liubov Petelytska², Havard Fretheim¹, Trond Mogens Aaløkken³, Mike Becker⁴, Cathrine Brunborg⁵, Cosimo Bruni⁶, Christian Clarenbach⁷, Phuong Phuong Diep⁸, Rucsandra Dobrota⁶, Michael Durheim⁹, Muriel Elhai¹⁰, Thomas Frauenfelder¹¹, Suzana Jordan⁶, Emily Langballe¹², Oyvind Midtvedt¹, Carina Mihai⁶, Oyvind Molberg¹³ and Oliver Distler⁶, ¹Oslo University Hospital, Oslo, Norway, ²Bogomolets National Medical University, Kyiv, Ukraine, ³Dept of Radiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁵Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁷Dept of Pulmonology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁸Dept of Respiratory diseases, University Hospital Oslo, Oslo, Norway, ⁹Dept of Respiratory diseases, Oslo University Hospital, Oslo, Norway, ¹⁰University Hospital zurich, University of Zurich, Zurich, Switzerland, ¹¹Dept of Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ¹²Universitetet i Oslo, Oslo, Norway, ¹³Dept of Rheumatology, University Hospital Oslo, Oslo, Norway
Background/Purpose: We have previously shown that short term progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) is associated with mortality. However, it is…
Abstract Number: 0949 • ACR Convergence 2023
Development of Interstitial Pneumonia with Autoimmune Features in Conditional Tgfb3 Deletion
Toshihiko Komai¹, Tomohisa Okamura², Masanori Kono¹, Kazuhiko Yamamoto³ and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: We found that TGF-β3 regulates humoral immunity in a context-dependent manner [1]. Recent genome-wide association study reveals that TGF-β3 might be a novel target…

« Previous Page
1
…
8
9
10
11
12
…
39
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].